Three month, multi-site, double blind, randomized, placebo-controlled, parallel-group trial is designed to assess the safety, tolerability and potential effect of anatabine in subjects with Alzheimer’s disease.
Previous tissue studies, which were conducted in a laboratory setting and in animal research, demonstrated that the anatabine citrate used in Anatabloc has shown to be effective in lowering amyloid levels and other markers of inflammation.
The company is expecting to enroll 120 subjects with mild to moderate Alzheimer’s disease to further evaluate tolerability, safety, blood levels of inflammatory markers, and functional status.
In addition to the Roskamp Institute site, the study is also being conducted at the Beaumont Hospital in Royal Oak, Michigan, US.
Roskamp Institute president and CEO Michael Mullan said, "We also have observed the anti-inflammatory effects of anatabine (the active ingredient of Anatabloc) in laboratory tests which is why we anticipate evidence of anti-inflammatory effects in this population."